Alnylam Pharmaceuticals have shown a massive contribution to **gene silencing** technology, often referred to as **RNAi** drugs. The company announced a multi-regional partnership expansion with **Medison Pharma**. Despite a tone of hesitancy, insiders of Alnylam have **sold** US$4.3m of shares recently. This follows a tough path painted by experts for significant **ATTR-CM readout**. However, the company managed an impressive performance in Q1. Their diagnostic campaign for hereditary **ATTR amyloidosis** has fostered early diagnoses. Alnylam's **strategic SWOT insight** suggests corporate maneuvers, including a **stake adjustment** by **Baillie Gifford**. FDA rejection of Alnylam's **heart-disease drug** for expanded use in the US comes as a setback, but the firm celebrates a second phase 2 win for the **blood pressure med** with **Roche**. Even though the FDA had doubts, Alnylam won expert support for **Onpattro**. Alnylam's pioneering role in **medical breakthroughs** with **FDA-approved RNAi treatments** shows promise. Furthermore, investors who purchased shares five years ago experienced a handsome gain of 63%. Overall, Alnylam looks set for continued success, leveraging its strategic strengths and innovative edge.
Alnylam Pharmaceuticals News Analytics from Sun, 23 Jul 2023 07:00:00 GMT to Thu, 13 Jun 2024 16:00:00 GMT -
Rating -1
- Innovation 8
- Information 7
- Rumor -2
